Company Overview of Visterra, Inc.
Visterra, Inc. engages in the discovery and development of products for the prevention, treatment, and diagnosis of infectious diseases. The company focuses on seasonal and pandemic influenza. Its products include therapeutic agents for influenza; vaccines for pandemic and seasonal influenza; and a prototype for the first functional influenza diagnostic that identifies the subtype and extent of human transmissibility of various influenza viruses. Visterra, Inc. was formerly known as Parasol Therapeutics, Inc. and changed its name to Visterra, Inc. in May 2010. The company was founded in 2007 and is based in Cambridge, Massachusetts.
One Kendall Square
Cambridge, MA 02139
Founded in 2007
Key Executives for Visterra, Inc.
Chief Financial Officer and Chief Operating Officer
Compensation as of Fiscal Year 2014.
Visterra, Inc. Key Developments
Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM
Jan 10 14
Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Brian J. G. Pereira, Chief Executive Officer, President and Director.
Visterra Inc. Acquires Exclusive Patent License for Monoclonal Antibodies Against Dengue Virus from Massachusetts Institute of Technology
Dec 2 13
Visterra Inc. announced that it has secured an exclusive patent license from Massachusetts Institute of Technology (MIT) to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
Visterra, Inc. Announces Management Changes
Dec 2 13
Visterra, Inc. announced that it has deepened its executive management team by appointing two industry veterans to newly created roles, David Arkowitz has joined the company as Chief Operating Officer and Chief Financial Officer, and Greg Miller will serve as Vice President of Business Development and Strategic Planning. Most recently, Mr. Arkowitz was at Mascoma Corporation, where he served as Chief Financial Officer and General Manager, Mascoma Grain Tech. Prior to joining Mascoma, he was Chief Financial Officer and Chief Business Officer of AMAG Pharmaceuticals. Most recently, Mr. Miller served as Vice President of Business and Corporate Development at Concert Pharmaceuticals since 2010. Prior to that, he was Senior Director of Business Development and Corporate Strategy at AMAG Pharmaceuticals from 2008 to 2010.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|